The efficacy of imatinib (trade name Gleevec), a CD117 inhibitor, is determined by the mutation status of CD117: When the mutation has occurred in exon 11 (as is the case many times in GISTs), the tumors are responsive to imatinib.
A eficacia do fármaco inhibidor de CD117 imatinib (nome comercial Gleevec) está determinada polo status de mutación de CD117: Cando a mutación tivolugar no exónn 11 (como ocorre en moitos casos en tumores estromais gastrointestinais), os tumores responde ao imatinib.